HomeCompareEFTRW vs SBUX

EFTRW vs SBUX: Dividend Comparison 2026

EFTRW yields 333333.33% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value
10 years
EFTRW
EFTRW
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full EFTRW calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — EFTRW vs SBUX

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFTRWSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFTRW + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFTRW pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + SBUX for your $10,000?

EFTRW: 50%SBUX: 50%
100% SBUX50/50100% EFTRW
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

EFTRW
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-13.6
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys
0
SBUX buys
0
No recent congressional trades found for EFTRW or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFTRWSBUX
Forward yield333333.33%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$8.099219044190773e+31M$167.0K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$71,136.45
Total dividends collected$8.098906375781879e+31M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: EFTRW vs SBUX ($10,000, DRIP)

YearEFTRW PortfolioEFTRW Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,121$420.68+$33.33MEFTRW
2$103,911,171,366$103,875,493,250.26$12,548$648.40+$103911.16MEFTRW
3$302,644,656,190,810$302,533,471,237,448.00$14,440$1,013.98+$302644656.18MEFTRW
4$823,817,797,451,856,400$823,493,967,669,732,100.00$17,068$1,617.30+$823817797451.84MEFTRW
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$20,912$2,649.52+$2095836995961804.00MEFTRW
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$26,875$4,499.29+$4983251920823461888.00MEFTRW
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$36,771$8,014.12+$1.1073835968753322e+22MEFTRW
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$54,542$15,197.11+$2.2999277308531335e+25MEFTRW
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$89,602$31,242.49+$4.464390519999121e+28MEFTRW
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$167,011$71,136.45+$8.099219044190773e+31MEFTRW

EFTRW vs SBUX: Complete Analysis 2026

EFTRWStock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this EFTRW vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs SCHDEFTRW vs JEPIEFTRW vs OEFTRW vs KOEFTRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.